A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)

Amyloid

Volumn 9, Issue 1, 2002, Pages 24-30

  Gertz, Morie A ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Cheson, Bruce D ^a   Barlogie, Bart ^a   Kyle, Robert A ^a   Palladini, Giovanni ^a   Geyer, Susan M ^a   Merlini, Giampaolo ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloid; Amyloidosis; Anthracycline; Cardiomyopathy; Chemotherapy; Nephrotic syndrome

Indexed keywords

4' IODOESORUBICIN; BILIRUBIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; HEART EJECTION FRACTION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; TREATMENT OUTCOME;

EID: 0036130774     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120209072441     Document Type: Article

References (16)

1. Amyloidosis
2. Response rates and survival in primary systemic amyloidosis
3. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
4. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
5. Primary systemic amytoidosis. Comparison of melphalan/prednisone versus colchicine
6. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients
7. Treatment of primary amyloidosis
8. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon
9. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG)
10. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis
11. New drug therapy of amyloidoses: Resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin
12. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis
13. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update
14. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4′-iodo-4′-deoxydoxorubicin
15. 4′-Iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid
16. The molecular interaction of 4′-iodo-4′-deoxydoxorubicin with Leu-55Pro transthyretin "amyloid-like" oligomer leading to disaggregation